|Videos|May 31, 2023
Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
2
New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer
3
CEA-High Expression Shows Early Promise as a Biomarker for BG-C477 in NSCLC
4
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
5